Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amneal Pharmaceuticals ( (AMRX) ) has shared an update.
On February 27, 2026, Amneal reported that fourth-quarter 2025 net revenue rose 11% year over year to $814 million, with GAAP net income swinging to a $35 million profit from a $31 million loss and adjusted EBITDA climbing 13% to $175 million. Specialty sales jumped 38% on strong uptake of CREXONT and UNITHROID, while Affordable Medicines slipped 1% and AvKARE grew 24%, highlighting the firm’s shift toward higher-margin branded and government-channel businesses.
For full-year 2025, net revenue increased 8% to $3.02 billion and net income improved to $72 million from a $117 million loss, as adjusted EBITDA rose 10% to $688 million and adjusted diluted EPS advanced to $0.83 from $0.58. Management’s 2026 guidance calls for modest top-line growth to $3.05–$3.15 billion and further margin expansion, signaling confidence in continued gains from new product launches, particularly in Affordable Medicines and AvKARE, and reinforcing Amneal’s trajectory of six consecutive years of execution and growth.
The most recent analyst rating on (AMRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
AMRX scores as moderate overall: technical momentum is strong and the earnings call featured raised guidance, but underlying financial profitability remains thin and valuation is a major headwind due to the extremely high P/E. Recent events are mixed, with interest savings offset by opioid settlement obligations.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, N.J., is a diversified global biopharmaceutical company focused on expanding access to affordable and innovative medicines. Its portfolio of about 300 complex generics, specialty and biosimilar products underpins three segments: Affordable Medicines, branded Specialty therapies in neurology and endocrinology, and AvKARE distribution to U.S. federal, retail and institutional customers.
Founded in 2002 and led by co-CEOs Chirag and Chintu Patel, Amneal delivers more than 160 million prescriptions annually, primarily in the U.S. The company’s Affordable Medicines unit spans retail, injectable and biosimilar offerings, while its Specialty franchise includes branded treatments for Parkinson’s disease, migraine and thyroid disorders, and AvKARE broadens reach across government and institutional channels.
Average Trading Volume: 2,455,840
Technical Sentiment Signal: Buy
Current Market Cap: $4.61B
Find detailed analytics on AMRX stock on TipRanks’ Stock Analysis page.